Physicians who are dealing with gynecological tumors have a limited experience of how to deal with the complications and toxicity associated with immunotherapy, suggests Alexandra Leary, MD, PhD, of the Gustave Roussy Institute of Oncology, Paris, France. To resolve this, Dr Leary suggests an interdisciplinary network comprised of consultants with more substantial experience within the field of immunotherapy, such as lung cancer specialists. She notes the substantial differences between the toxicity profiles of chemo and immunotherapies, with immunotherapy toxicity having the potential to be severe, sudden and life-threatening. Thus, it is essential for physicians to liaise, as well as to reiterate the benefit immunotherapy has over potential risk. This was explored at the UK Oncology Forum (OF) 2018, held in Liverpool, UK.
